Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model

Background: Preclinical drug development studies rarely consider the impact of a candidate drug on established metastatic disease. This may explain why agents that are successful in subcutaneous and even orthotopic preclinical models often fail to demonstrate efficacy in clinical trials. It is reaso...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Jessica, Baker, Jennifer, Song, Justin, Kyle, Alastair, Minchinton, Andrew, Bally, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231937/
https://www.ncbi.nlm.nih.gov/pubmed/34199298
http://dx.doi.org/10.3390/ijms22126336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231937/
https://www.ncbi.nlm.nih.gov/pubmed/34199298
http://dx.doi.org/10.3390/ijms22126336

Ejemplares similares